טוען...
Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubul...
שמור ב:
| הוצא לאור ב: | Medicina (Kaunas) |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6572507/ https://ncbi.nlm.nih.gov/pubmed/31117208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55050176 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|